Aridis Pharmaceuticals, Inc. (ARDS)

OTCMKTS: ARDS · Delayed Price · USD
0.0772
+0.0002 (0.26%)
Feb 29, 2024, 2:31 PM EST - Market open

Company Description

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.

Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S.

aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia.

The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S.

aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11.

In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1.

The company was founded in 2003 and is headquartered in Los Gatos, California.

Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals logo
Country Canada
Founded 2003
IPO Date Aug 10, 2018
Industry Biotechnology
Sector Healthcare
Employees 37
CEO Dr. Vu L. Truong Ph.D.

Contact Details

Address:
983 University Avenue, Bldg. B
Los Gatos, California 95032
United States
Phone (408) 385-1742
Website aridispharma.com

Stock Details

Ticker Symbol ARDS
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001614067
CUSIP Number 040334104
ISIN Number US0403341045
Employer ID 32-0074500
SIC Code 2834

Key Executives

Name Position
Dr. Eric J. Patzer Ph.D. Founder and Executive Chairman
Dr. Vu L. Truong Ph.D. Founder, Chief Executive Officer, Chief Scientific Officer and Director
Dr. Hasan Jafri M.D. Chief Medical Officer
Tamara S. Allen Vice President of Finance
Jeffrey J. Fessler Esq., J.D. Acting General Counsel

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 16, 2024 8-K Current Report
Dec 18, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Dec 18, 2023 8-K Current Report
Dec 15, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 6, 2023 10-Q Quarterly Report
Nov 3, 2023 8-K Current Report
Nov 3, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Nov 3, 2023 ARS Filing